Showing results (31-40 of 164) with videos related to

Sort By:
Pageof 17
Blood|February 8, 2012
Second malignancies after multiple myeloma: from 1960s to 2010sAnish Thomas, Sham Mailankody, Neha Korde, et al.
Leukemia & Lymphoma|October 21, 2010
Molecular and biologic markers of progression in monoclonal gammopathy of undetermined significance to multiple myelomaSham Mailankody, Esther Mena, Constance M Yuan, et al.
Blood|August 10, 2016
Atypical Pneumocystis jirovecii pneumonia in previously untreated patients with CLL on single-agent ibrutinibInhye E Ahn, Theresa Jerussi, Mohammed Farooqui, et al.
Clinical Rheumatology|November 10, 2009
The silent progression of metastatic malignancy during the treatment with soluble tumor necrosis factor receptorInhye E Ahn, Ji Hyeon Ju, Kwi Young Kang, et al.
Leukemia & Lymphoma|November 7, 2017
CAR T cell therapy for multiple myeloma: where are we now and where are we headed?Arnab Ghosh, Sham Mailankody, Sergio A Giralt, et al.
Nature Reviews. Clinical Oncology|January 28, 2015
Minimal residual disease in multiple myeloma: bringing the bench to the bedsideSham Mailankody, Neha Korde, Alexander M Lesokhin, et al.
The Laryngoscope|July 28, 2010
Cost analysis of asymmetric sensorineural hearing loss investigationsYuShan L Wilson, Michele M Gandolfi, Inhye E Ahn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 20, 2021
Select Antitumor Cytotoxic CD8+ T Clonotypes Expand in Patients with Chronic Lymphocytic Leukemia Treated with IbrutinibMaria Joao Baptista, Sivasubramanian Baskar, Erika M Gaglione, et al.
Pageof 17